Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-02
2011-08-02
Kelly, Robert M (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200
Reexamination Certificate
active
07989426
ABSTRACT:
The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial cells associated with neovascularization of the choroid such that choroidal neovascularization is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating ocular neovascularization, wherein the method comprises directly administering to the eye a nucleic acid sequence encoding a therapeutic factor to promote apoptosis of endothelial cells associated with neovascularization, such that the nucleic acid is expressed thereby producing the therapeutic factor to treat ocular neovascularization prophylactically or therapeutically.
REFERENCES:
patent: 4405712 (1983-09-01), Vande Woude
patent: 4497796 (1985-02-01), Salser et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 5190931 (1993-03-01), Inouye
patent: 5208149 (1993-05-01), Inouye
patent: 5518913 (1996-05-01), Massie et al.
patent: 5583009 (1996-12-01), Palmiter et al.
patent: 5641749 (1997-06-01), Yan et al.
patent: 5710136 (1998-01-01), Robinson et al.
patent: 5770580 (1998-06-01), Ledley et al.
patent: 5792751 (1998-08-01), Ledley et al.
patent: 5801156 (1998-09-01), Robinson et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5827702 (1998-10-01), Cuthbertson
patent: 5840686 (1998-11-01), Chader et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5891690 (1999-04-01), Massie et al.
patent: 5962311 (1999-10-01), Wickham et al.
patent: 5994106 (1999-11-01), Kovesdi et al.
patent: 6113913 (2000-09-01), Brough et al.
patent: 6168941 (2001-01-01), Liu
patent: 6204251 (2001-03-01), Cuthbertson
patent: 6225113 (2001-05-01), Brough et al.
patent: 6228646 (2001-05-01), Hardy
patent: 6288024 (2001-09-01), Bouck et al.
patent: 6410298 (2002-06-01), Crouzet et al.
patent: 2002/0064870 (2002-05-01), Briand et al.
patent: 2002/0168342 (2002-11-01), Wang et al.
patent: 2003/0158112 (2003-08-01), Campochiaro
patent: 95/28533 (1996-03-01), None
patent: 95/38477 (1996-05-01), None
patent: 2000/31294 (2000-12-01), None
patent: 2053187 (1993-04-01), None
patent: 2117668 (1995-09-01), None
patent: 1083229 (2001-03-01), None
patent: 2707664 (1995-01-01), None
patent: 2718749 (1995-10-01), None
patent: WO 93/24529 (1993-12-01), None
patent: WO 94/01139 (1994-01-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 94/12649 (1994-06-01), None
patent: WO 94/20146 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 94/28152 (1994-12-01), None
patent: WO 94/28938 (1994-12-01), None
patent: WO 95/00655 (1995-01-01), None
patent: WO 95/16722 (1995-06-01), None
patent: WO 95/19182 (1995-07-01), None
patent: WO 95/26411 (1995-10-01), None
patent: WO 95/27071 (1995-10-01), None
patent: WO 95/33480 (1995-12-01), None
patent: WO 95/34671 (1995-12-01), None
patent: WO 96/13276 (1996-05-01), None
patent: WO 96/14061 (1996-05-01), None
patent: WO 96/18418 (1996-06-01), None
patent: WO 97/21826 (1997-06-01), None
patent: WO 97/37542 (1997-10-01), None
patent: WO 97/47307 (1997-12-01), None
patent: WO 98/49321 (1998-11-01), None
patent: WO 99/04806 (1999-02-01), None
patent: WO 99/16889 (1999-04-01), None
patent: WO 99/25861 (1999-05-01), None
patent: WO 99/26480 (1999-06-01), None
patent: WO 99/29345 (1999-06-01), None
patent: WO 00/15822 (2000-03-01), None
patent: WO 00/52479 (2000-09-01), None
patent: WO 00/54813 (2000-09-01), None
patent: WO 01/44280 (2001-06-01), None
patent: WO 02/24234 (2002-03-01), None
Stellmach, et al. (2001) Proceedings of the National Academy of Science, USA., 98(5): 2593-97.
Demetriades, et al. (2008) Journal of Ocular Pharmacology and Therapeutics, 42(1): 70-79.
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins,”Proc. Natl. Acad. Sci. USA, 92 (23): 10457-10461 (Nov. 1995).
Amalfitano et al., “Production and characterization of improved adenovirus vectors with E1, E2b, and E3 genes deleted,”J. Virol., 72 (2): 926-933 (Feb. 1998).
Armentano et al., “Characterization of an adenovirus gene transfer vector containing an E4 deletion,”Hum. Gene Ther., 6: 1343-1353 (Oct. 1995).
Auricchio et al., “Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye,”Mol. Ther., 6 (2): 238-242 (Aug. 2002).
Baffi et al., “Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor,”Invest. Ophthalmol. Visual Sci., 41 (11): 3582-3589 (Oct. 2000).
Bainbridge et al., “Gene therapy for ocular angiogenesis,”Clin. Sci., 104: 561-575 (2003).
Barr et al., “Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus,”Gene Ther., 1: 51-58 (1994).
Benihoud et al., “Adenovirus vectors for gene therapy,”Curr. Opin. Biotechnol., 10: 440-447 (1999).
Berkner et al., “Abundant expression of polyomavirus middle T antigen and dihydrofolate reductase in an adenovirus recombinant,”J. Virol., 61 (4): 1213-1220 (Apr. 1987).
Berkner et al., “Generation of adenovirus by transfection of plasmids,”Nucl. Acids Res., 11 (17): 6003-6020 (1983).
Berkner, “Development of adenovirus vectors for the expression of heterologous genes,”BioTechniques, 6 (7): 616-629 (1988).
Boucher et al., “Gene therapy for cystic fibrosis using E1-deleted adenovirus: A phase I trial in the nasal cavity,”Hum. Gene Ther., 5: 615-639 (1994).
Brough et al. “Multiple functions of the adenovirus DNA-binding protein are required for efficient viral DNA synthesis,”Virol., 196: 269-281 (1993).
Brough et al., “A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4,”J. Virol., 70 (9): 6497-6501 (Sep. 1996).
Brough et al., “Construction, characterization, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein,”Virology, 190: 624-634 (1992).
Chen et al., “Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase,”Proc. Natl. Acad. Sci USA, 94: 5798-2803 (May 1997).
Chen et al., “The activation of trans-acting factors in response to hypo- and hyper-osmotic stress in mammalian cells,”in Environmental Stressors and Gene Responses(Storey et al., eds): 141-155 (Elsevier Science Ltd., Amsterdam, Netherlands, Jan. 2000).
Crystal et al., “Administration of an adenovirus containing the humanCFTRcDNA to the respiratory tract of individuals with cystic fibrosis,”Nat. Genet., 8, 42-51 (Sep. 1994).
Crystal, “Transfer of genes to humans: Early lessons and obstacles to success,”Science, 270: 404-410 (Oct. 20, 1995).
Davidson et al., “Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector,”J. Virol., 61 (4): 1226-1239 (Apr. 1987).
Dawson et al., “Pigment epithelium-derived factor: A potent inhibitor of angiogenesis,”Science, 285 (5425): 245-248 (Jul. 9, 1999).
Dejneka et al., “Pharmacologically regulated gene expression in the retina following transduction with viral vectors,”Gene Ther., 8 (6): 442-446 (Mar. 2001).
Deonarain, “Ligand-targeted receptor-mediated vectors for gene delivery,”Exp. Opin. Ther. Pat., 8 (1): 53-69 (1998).
Eck et al., inThe Pharmacological Basis of Therapeutics, 9th Ed. (Goodman et al., eds.): 77-101 (McGraw Hill, New York, NY 1996).
Engelhardt et al., “Ablation of
Campochiaro Peter A.
Gehlbach Peter
Johns Hopkins University School of Medicine
Kelly Robert M
Leydig , Voit & Mayer, Ltd.
LandOfFree
Selective induction of apoptosis to treat ocular disease by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective induction of apoptosis to treat ocular disease by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective induction of apoptosis to treat ocular disease by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731477